These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1701497)

  • 1. Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the fraction of human prostatic carcinoma.
    Oomens EH; van Steenbrugge GJ; van der Kwast TH; Schröder FH
    J Urol; 1991 Jan; 145(1):81-5. PubMed ID: 1701497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma.
    McLoughlin J; Foster CS; Price P; Williams G; Abel PD
    Br J Urol; 1993 Jul; 72(1):92-7. PubMed ID: 7511972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study of growth fraction on fine needle aspirated prostatic tissue smear using monoclonal antibody Ki-67].
    Sai S; Takashi M; Miyake K; Koshikawa T
    Hinyokika Kiyo; 1991 Aug; 37(8):881-6. PubMed ID: 1957731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer.
    Gallee MP; Visser-de Jong E; ten Kate FJ; Schroeder FH; Van der Kwast TH
    J Urol; 1989 Nov; 142(5):1342-6. PubMed ID: 2478729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies.
    Casella R; Bubendorf L; Sauter G; Moch H; Mihatsch MJ; Gasser TC
    J Urol; 1998 Aug; 160(2):406-10. PubMed ID: 9679888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki-67 antibody immunostaining in benign and malignant human prostatic disease.
    Lloyd SN; Brown IL; Leake RE
    Int J Biol Markers; 1992; 7(4):256-9. PubMed ID: 1283399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of the nuclear proliferative index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia, and prostatic carcinoma.
    Tamboli P; Amin MB; Schultz DS; Linden MD; Kubus J
    Mod Pathol; 1996 Oct; 9(10):1015-9. PubMed ID: 8902840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limiting the diagnosis of atypical small glandular proliferations in needle biopsies of the prostate by the use of immunohistochemistry.
    Helpap B; Köllermann J; Oehler U
    J Pathol; 2001 Mar; 193(3):350-3. PubMed ID: 11241415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of estrogen receptor β and Ki 67 in benign & malignant human prostate lesions by immunohistochemistry.
    Grover SK; Agarwal S; Gupta S; Wadhwa N; Sharma N
    Pathol Oncol Res; 2015 Jul; 21(3):651-7. PubMed ID: 25527409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
    Bretton PR; Evans WP; Borden JD; Castellanos RD
    Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
    Sasor A; Wagrowska-Danilewicz M; Danilewicz M
    Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy in core biopsy of the prostate. An autopsy study.
    Horndalsveen Berild G; Nielsen K
    Urol Int; 1986; 41(4):276-8. PubMed ID: 2431526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".
    He H; Magi-Galluzzi C; Li J; Carver P; Falzarano S; Smith K; Rubin MA; Zhou M
    Am J Surg Pathol; 2011 Apr; 35(4):608-14. PubMed ID: 21383613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth fractions in human prostatic carcinoma determined by Ki-67 immunostaining.
    Raymond WA; Leong AS; Bolt JW; Milios J; Jose JS
    J Pathol; 1988 Oct; 156(2):161-7. PubMed ID: 3058914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of fine needle aspiration cytology (FNAC) in the diagnosis of prostatic lesions with histologic correlation.
    Saleh AF; Nahar Rahman AJ; Salam MA; Islam F
    Bangladesh Med Res Counc Bull; 2005 Dec; 31(3):95-103. PubMed ID: 17549870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell proliferation in prostatic carcinoma: comparative analysis of Ki-67, MIB-1 and PCNA.
    Hepburn PJ; Glynne-Jones E; Goddard L; Gee JM; Harper ME
    Histochem J; 1995 Mar; 27(3):196-203. PubMed ID: 7797424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostatic aspirates. A cytomorphologic analysis with emphasis on well-differentiated carcinoma.
    Kline TS; Kannan V
    Diagn Cytopathol; 1985; 1(1):13-7. PubMed ID: 2424681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer.
    Padmanabhan V; Callas P; Philips G; Trainer TD; Beatty BG
    J Clin Pathol; 2004 Oct; 57(10):1057-62. PubMed ID: 15452160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.